TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Presentado sáb, 7 nov · 14:00 GMT-6LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After StrokeTodos los ensayos Late-Breaking Science →

REDUCE

2026

REDUCE: Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke

In stroke survivors with uncontrolled high blood pressure, spironolactone added to usual care was associated with home systolic blood pressure nearly 8 mm Hg lower at three months compared with usual post-stroke care, with statistical significance not reported.

Resultado

Variable principal: Change in home systolic blood pressure at 3 months

Home systolic blood pressure was nearly 8 mm Hg lower at three months with spironolactone than with usual post-stroke care. P values and confidence intervals were not reported. The blood pressure goal was reached by 52% vs 30% at three months. Diastolic blood pressure dropped by about 4 mm Hg on average compared with standard care, and systolic blood pressure was about 7 mm Hg lower at six months. Serious side effects requiring hospitalisation occurred in 15% vs 16%. High potassium levels were present in about 4% of the spironolactone group.

Publicación original
Subtema
Secondary stroke prevention
Diseño
Phase 2 randomised trial (Yale University; 5 US sites) of spironolactone added to usual antihypertensive treatment versus usual treatment after intracerebral haemorrhage or ischaemic stroke
Incluidos
160 pacientes
Fuente
Cohen JB, et al. Presented at AHA Scientific Sessions 2026, 7 November. American Heart Association newsroom release. Not yet published.

Discusión y crítica

REDUCE suggests that adding spironolactone to usual care after stroke lowers home systolic blood pressure over three to six months, but the release gives only approximate differences with no confidence intervals or P values. The comparator was usual care rather than another antihypertensive, the trial was open label, and the spironolactone group was taking more blood pressure medicines at three months (2.6 vs 2.1). Enrolment stopped early at 160 of 200 planned participants, and about 15% had no three-month readings. Blood pressure is a surrogate here: the trial was not designed to show whether spironolactone prevents another stroke or heart attack.